Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. The company is headquartered in Wilmette, Illinois and currently employs 16 full-time employees. The company went IPO on 2019-12-19. The firm developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
Follow-Up Questions
Monopar Therapeutics Inc의 CEO는 누구입니까?
Dr. Chandler Robinson은 2014부터 회사에 합류한 Monopar Therapeutics Inc의 Chief Executive Officer입니다.
MNPR 주식의 가격 성능은 어떻습니까?
MNPR의 현재 가격은 $62.99이며, 전 거래일에 decreased 4.92% 하였습니다.
Monopar Therapeutics Inc의 주요 사업 주제나 업종은 무엇입니까?
Monopar Therapeutics Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Monopar Therapeutics Inc의 시가총액은 얼마입니까?
Monopar Therapeutics Inc의 현재 시가총액은 $388.6M입니다
Monopar Therapeutics Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 10명의 분석가가 Monopar Therapeutics Inc에 대한 분석 평가를 실시했으며, 이는 2명의 강력한 매수, 9명의 매수, 2명의 보유, 0명의 매도, 그리고 2명의 강력한 매도를 포함합니다
